GlassScriptPhysician profile
Emanuel E Mamatas
NPI 1891768511
$16,797.39
in general payments reported to CMS, 2019-2025
42 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,181 · 2020: $1,958 · 2021: $2,921 · 2022: $2,880 · 2023: $2,648 · 2024: $2,920 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,857.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,131.19 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $2,739.36 | 2019-2025 | |
| Novo Nordisk INC | $1,675.14 | 2019-2024 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,666.95 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Allergan, INC. | $671.70 | 2019-2020 | |
| Lilly USA, LLC | $666.20 | 2019-2025 | Mounjaro, Kisunla, Emgality |
| Amgen INC. | $562.98 | 2019-2024 | Tezspire, Evenity, Prolia |
| Avanir Pharmaceuticals, INC. | $562.97 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $519.02 | 2019-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $500.18 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $493.60 | 2019-2024 | Xarelto |
| Gilead Sciences, INC. | $447.17 | 2020-2024 | Epclusa |
| Merck Sharp & Dohme LLC | $430.74 | 2019-2023 | Verquvo, Lagevrio |
| Biohaven Pharmaceutical Holding Company LTD. | $354.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $332.48 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emanuel Mamatas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.